Cheapest Compounded Tirzepatide: Price Comparison & Pharmacy Guide 2026
Compare the actual cost of tirzepatide care using current manufacturer offers, written compounded quotes and the SurpassMD starting offer below. Product, eligibility, included services and supply period matter; price alone does not establish clinical equivalence, quality or a lawful compounding pathway.
SurpassMD offers compounded tirzepatide as low as $177/month; the SurpassMD offer below states its service terms and shared-ownership disclosure. Prescription and treatment eligibility remain subject to licensed clinician review.
Current Price References and Quote Comparisons
| Option | Price reference | Scope |
|---|---|---|
| SurpassMD compounded tirzepatide program | As low as $177/month | See offer, included services and shared-ownership disclosure below; clinician determines eligibility |
| Zepbound single-patient-use KwikPen | $299 starting strength; $399 at 5 mg; $449 offer for 7.5–15 mg | 28-day fills; higher-strength purchase-offer/refill conditions apply; see source terms below |
| Other compounded quote | Exact written quote required | Compare product, prescribed quantity, services and lawful dispensing conditions |
Prices checked October 27, 2026: Lilly’s Zepbound KwikPen self-pay terms list as-low-as $299 for 2.5 mg, $399 for 5 mg and $449 for 7.5–15 mg per 28-day prescription under the applicable purchase offer. Continuing the $449 offer requires the specified refill purchase within 45 days; regular higher-strength prices can be higher. Self-pay purchases cannot be submitted to insurance or credited toward its deductible. Taxes/fees and eligibility apply. The 2.5 mg strength is a starting dose, not a maintenance option. These are KwikPen terms, not a quote for every pen or vial.
Mounjaro’s separate savings program requires eligible commercial insurance and an approved-use prescription. Covered single-dose pens may cost as little as $25 for up to a three-month fill, subject to caps; commercial insurance without coverage has a separate as-low-as $499 one-month offer. Government beneficiaries are excluded from that commercial card. These programs are not interchangeable with Zepbound self-pay or a compounded prescription.
Price Is Not a Quality Test
Compare total cost, clinical suitability, lawful access and the actual product evidence. A cheaper option is not automatically less pure, and a higher-priced or accredited service is not automatically more effective. This guide does not assign a safety ranking from price or substitute an advertised quote for a pharmacist’s product assessment.
Why Prices Vary: What You're Actually Paying For
Compare a written quote for the exact prescribed preparation and supply period: medication amount/concentration, visit or membership fees, dispensing, supplies, shipping, required monitoring, cancellation and refund terms. Distinguish an introductory price from later refills and calculate the total actually payable. A quoted month may mean 28 days, 30 tablets or another specified quantity; do not compare those as identical calendar-year coverage.
Questions for Lower Quotes
A lower quote may include fewer services or a different supply period. Ask for the actual preparation, quantity and recurring charges; do not infer reduced testing or a quality tier from the dollar amount.
Questions for Higher Quotes
A higher quote may bundle more care or services, but the provider must specify them. Price does not establish independent testing, greater purity, longer stability or better clinical results.
Comparing Actual Compounding Services
This page does not verify a market-wide cheapest or top pharmacy. Compare the SurpassMD offer below with actual written pharmacy quotes and manufacturer terms, keeping product identity and eligibility separate.
Service and Product Checks
Assess the responsible pharmacy’s applicable licenses and shipping authority, exact preparation, labeling, actual content, quality controls and product-specific stability. PCAB accreditation can provide useful information about a practice’s standards; it is different from state licensure and does not prove a particular vial’s potency, safety or clinical equivalence. Price, business age and online reviews are not laboratory measurements. An external COA addresses the sampled material and tests reported, not every quality question.
How to Vet a Compounding Pharmacy: Complete Checklist
Begin with the prescriber and dispensing pharmacy identities, applicable state authority and the exact preparation. Then review product documentation, pricing and follow-up responsibilities separately.
Licensing and Accreditation Are Distinct
Verify applicable state pharmacy authority and the prescriber’s practice authority. Accreditation is a separate credential, not a substitute for either. Do not assume every pharmacy must hold an identical voluntary accreditation or controlled-substance registration merely to dispense this drug.
Quality & Testing (Critical):
Ask what the finished-product testing measures, which lot it represents, and whether actual content, identity, microbial controls and stability are addressed. A COA does not establish effectiveness or every safety question.
Reputation & Customer Service:
Reviews can describe communication and service experiences. They cannot establish sterility, concentration, authentic ingredients or a fixed probability of treatment success. Ask who addresses urgent problems and how complaints are handled.
Pricing Transparency:
Get the amount payable today and at later refills in writing. Include membership, supplies, shipping, monitoring and cancellation terms rather than comparing only a headline medicine price.
Red Flags: Pharmacies to Avoid
Investigate an unverifiable pharmacy, missing product/lot information, unsupported medical promises or unclear charges. No arbitrary dollar threshold, review count or business age establishes contamination.
FDA Compounding Conditions in 2026
FDA’s current compounding update records tirzepatide shortage resolution in December 2024 and the end of the associated shortage-based enforcement-discretion periods in 2025. There is no ongoing blanket shortage authorization. Under 503A, restrictions on essentially copying commercially available drugs and other conditions apply; a prescriber-documented change producing a significant difference for an identified patient is distinct from price alone. 503B has separate bulk-substance and copy restrictions. A prescription, accreditation, added vitamin or online listing alone does not establish that a particular preparation qualifies. Lawful patient-specific compounding can meet important needs; this is neither universal permission nor a claim all compounding is prohibited.
Historical Context:
FDA’s dated shortage and enforcement updates distinguish the resolved national shortage from intermittent local stock issues. The past discretion was not a product approval or a permanent general authorization.
Proposals and Operative Rules
A proposal, nomination, pending review or predicted restriction is not an enacted rule. Check the operative requirements for the actual patient, compounder and preparation; do not rush purchases on a predicted closing window.
Price Comparison: Budget Strategies
Compare the same prescribed quantity and supply period, including refill terms and separate services. Confirm whether the price is a manufacturer self-pay offer, an insurance-adjudicated cost or a compounded-service quote.
Get Multiple Quotes:
Compare equivalent quantities and all recurring fees. Manufacturer self-pay offers and the SurpassMD starting offer are concrete price references; a fictional pharmacy-tier range is not a verified quotation.
Prepayment and Supply-Period Discounts
Prepayment discounts must be supported by an actual contract. Include cancellation/refund terms, clinical changes, supply limits and the actual beyond-use date; do not stockpile or buy a longer supply to meet an assumed savings target.
Telehealth Partnerships:
Identify the prescriber, dispensing pharmacy and what follow-up the service provides. A telehealth service may bundle clinical care and logistics; a pharmacy fill still requires appropriate prescribing and does not remove the need for follow-up. Neither channel is inherently cheaper or safer. The SurpassMD offer below provides its starting price, included clinician review, service details and ownership disclosure.
Prescription Transfers:
Ask the prescriber and pharmacies whether a transfer is appropriate and what it requires. Do not assume a new prescription guarantees lawful compounding, an interchangeable formulation or uninterrupted supply.
Quality vs. Price: Making the Right Choice
Tirzepatide is the ingredient in Mounjaro and Zepbound; it is not semaglutide. Compounded finished drugs are not FDA-approved and are not FDA-approved generics of those brands. A claimed shared ingredient does not establish the identity, exposure, stability, safety or effectiveness of the actual compounded product. Approved-brand clinical findings cannot be assigned to an untested compounded preparation.
When a Branded Offer Fits
Check whether the branded medicine is suitable and what its actual program or insurance terms require. A savings-card floor is not the amount every insured or uninsured patient pays.
When Patient-Specific Compounding Is Considered
A prescriber may identify a patient-specific need for a compounded preparation. The pharmacy must still assess the applicable conditions; a lower price, a denied claim or adding a vitamin does not establish a general exemption.
Evaluating an Unusually Low Quote
Ask whether an unusually low quote is introductory, requires prepayment or excludes clinical care or supplies. Check actual product and service documentation; do not assign a potency or contamination rate from the price.
Reconstitution & Storage: Budget Considerations
Use the dispensing pharmacist’s instructions and the actual preparation’s storage and beyond-use date. A powder is not automatically cheaper, longer-lived or appropriate for home mixing; a ready-to-use vial does not require routine reconstitution. Refrigeration or clear appearance cannot prove potency or sterility. For a warm/damaged shipment, provide the pharmacy with product, lot, time and temperature details and obtain a product-specific assessment before use; do not infer a universal discard rule or guaranteed replacement.
Powder Preparations
Do not choose a research powder or derive a home reconstitution method to reduce price. The prescribed finished product and pharmacist’s preparation instructions govern.
Ready-to-Use Preparations
A ready-to-use product has its own concentration, device, storage and beyond-use instructions. No generic 14–21-day or 30-day hierarchy establishes safety or savings.
Dated Prices and Actual Written Quotes
The live manufacturer terms above and the SurpassMD starting offer below are dated price references. Other pharmacy quotes must identify the pharmacy, preparation, quantity, included services and date; no unverified budget/premium tiers are presented as observed data.
Getting Started: Action Steps
Confirm treatment appropriateness and the legal dispensing pathway first, then obtain the exact written price and supply terms, review instructions, and arrange follow-up. Do not use the initial order as an informal purity or potency test.
Related Resources & Guides
Use the further reading below for product, cost and compounding context. Preparation arithmetic does not select a safe dose, mixing method or switching schedule.
Related reading: FDA compounding crackdown guide · FDA compounding crackdown guide · peptide reconstitution guide · peptide reconstitution guide · Compounded Tirzepatide: Complete Safety & Quality Guide · Is Compounded Tirzepatide Safe? What You Need to Know · Tirzepatide Cost Breakdown & Pricing · Tirzepatide Without Insurance: All Cost Options
Frequently Asked Questions
Compare a written quote for the exact preparation and supply period with the SurpassMD offer below and current branded self-pay or insurance terms. No universal pharmacy-price range or price-based safety threshold is established.
Quoted totals may differ in medicine quantity, visits, membership, dispensing, supplies and shipping. Ask what changes at later refills and what is refundable; do not infer quality from the price.
Check the pharmacy’s applicable licensing and shipping authority, actual preparation, relevant quality controls, stability information, and pharmacist access. Accreditation is separate from licensure and does not certify every vial.
Lower price is not a measured contamination or potency risk. Product evidence and lawful access matter; a high price or accreditation also does not guarantee safety.
FDA’s current records show that the shortage-based discretion periods ended in 2025. Present compounding remains subject to specific 503A/503B and state conditions; price, a prescription or added ingredients alone do not establish an exemption.
Compare clinical suitability, lawful access, the actual product and total care costs. A market-wide cheapest or safety ranking cannot be inferred from advertised amounts.
Investigate unverifiable authority, unclear ingredients/lot details, unsupported promises, evasive product documentation and hidden fees. Neither a new business nor a low price proves poor quality.
Use the relevant state board and any applicable FDA outsourcing-facility record, then separately verify a claimed accreditation with its issuer. Confirm the authority needed to dispense to the patient’s location; a directory listing is not product approval.